Holen Sie sich die Stockscreener-App
118.21
0.44%
-0.52
Handel nachbörslich:
118.21
Schlusskurs vom Vortag:
$118.73
Offen:
$119.5
24-Stunden-Volumen:
583.88K
Relative Volume:
0.64
Marktkapitalisierung:
$5.38B
Einnahmen:
$1.33B
Nettoeinkommen (Verlust:
$97.31M
KGV:
58.18
EPS:
2.0317
Netto-Cashflow:
$260.44M
1W Leistung:
-2.88%
1M Leistung:
+9.05%
6M Leistung:
+93.25%
1J Leistung:
+133.11%
1-Tages-Spanne:
$117.20
$120.50
1-Wochen-Bereich:
$117.00
$122.53
52-Wochen-Spanne:
$48.98
$123.77
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
118.21 | 5.38B | 1.33B | 97.31M | 260.44M | 2.0317 |
ABT
Abbott Laboratories
|
102.45 | 177.28B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.63 | 121.04B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
304.40 | 116.76B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.58 | 66.06B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
88.29 | 50.89B | 6.30B | 1.07B | 1.09B | 1.8406 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2026-05-22 | Hochstufung | BofA Securities | Neutral → Buy |
| 2026-05-12 | Bestätigt | Barrington Research | Outperform |
| 2025-12-15 | Herabstufung | Needham | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Bestätigt | Barrington Research | Outperform |
| 2025-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-06-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Haemonetics Gains 149.3% in a Year: What's Driving the Rally? - Zacks Investment Research
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term - Zacks Investment Research
Haemonetics: CSL Plasma Improves The Outlook, Not The Entry Point (Rating Downgrade) - Seeking Alpha
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo! Finance Canada
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength? - Zacks Investment Research
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength? - Yahoo Finance
Haemonetics (HAE) Jumped, What Is Behind The Move? - Yahoo Finance
Haemonetics (HAE) Surges Over 17% on Plasma Supply Deal with CSL - GuruFocus
Haemonetics Corporation Stock 12‑Month Price Target Raised to $120, Implies 18% Upside - TradingView
Haemonetics advances 17% on CSL supply deal (HAE:NYSE) - Seeking Alpha
Haemonetics (HAE) Jumps As Citi Hikes Price Target To $123 - Timothy Sykes
Haemonetics (HAE) Jumps As Citi Hikes Price Target To $123 - StocksToTrade
Haemonetics (HAE) Shares Skyrocket, What You Need To Know - Yahoo Finance
Haemonetics (HAE) Surges 12.8% to $114.69 - AlphaStreet
Haemonetics Stock Climbs As Citi Hikes Price Target On CSL Upside - StocksToTrade
Haemonetics (HAE) Stock Climbs After Citi Ups Price Target - www.timothysykes.com
Haemonetics (HAE) Stock Climbs After Citi Ups Price Target - Timothy Sykes
Haemonetics Jumps to 52-Week High as CSL Plasma Plans Full U.S. Device Rollout by 2027 - finance.biggo.com
Haemonetics jumps after strong Q4 results and fiscal 2027 outlook - Quiver Quantitative
Haemonetics Stock Hits 52-Week HighHere's Why - Benzinga
Haemonetics Stock Hits 52-Week HighHere's Why - Benzinga
Haemonetics Stock Hits 52-Week HighHere's Why - TradingView
Haemonetics Says CSL Plasma to Complete Rollout of Products by End-2027 - marketscreener.com
Haemonetics Stock Pops As Citi Hikes Price Target To $123 - StocksToTrade
Haemonetics (HAE) Jumps As Citi Hikes Price Target To $123 - Timothy Sykes
Why is Haemonetics stock surging today? - Investing.com
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices - Yahoo Finance
Haemonetics (HAE) Surges 12.8% to $114.69 - AlphaStreet
Haemonetics Soars 12% on CSL Update: Plasma Giant to Roll Out NexSys Across U.S. Centers - Yahoo Finance
Haemonetics stock hits 52-week high at 114.0 USD - Investing.com
BTIG raises Haemonetics stock price target on CSL Plasma deal - Investing.com
Why is Haemonetics stock surging today? - Investing.com
Haemonetics stock surges 17% on CSL Plasma supply deal update - Yahoo Finance
Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027 - marketscreener.com
Haemonetics (HAE) Secures Supply Deal with CSL Plasma for NexSys PCS Devices - GuruFocus
Haemonetics stock surges 17% on CSL Plasma supply deal update - Investing.com
Haemonetics gains after update on CSL supply deal (HAE:NYSE) - Seeking Alpha
Haemonetics: Non‑exclusive CSL Plasma supply deal; rollout expected by end‑2027 - TradingView
A rollout to all current U.S. CSL plasma centers is anticipated for Haemonetics (HAE), subject to change. - Stock Titan
CSL Expands Relationship With Haemonetics Corporation - TradingView
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo Finance
Haemonetics Q1 2027 Earnings Call Transcript - Benzinga
BTIG reiterates Buy rating on Haemonetics with $84 target - scanx.trade
Haemonetics stock heads into November 5 results with key benchmarks - AD HOC NEWS
Haemonetics stock heads into November 5 results after earnings beat - AD HOC NEWS
Haemonetics Corporation (NYSE: HAE) Share Price, HAE Stock News, HAE Share Price & Updates - kalkine.ca
Haemonetics Corporation (HAE) Stock forecasts - Yahoo Finance Singapore
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo! Finance Canada
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo Finance
Haemonetics sets Q2FY27 earnings release date for November 5 - scanx.trade
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.01%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):